PAM
IBRX icon

Paradigm Asset Management’s ImmunityBio IBRX Stock Holding History

Paradigm Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,500
Closed -$71.5K – 705
2016
Q2 		$71.5K Buy
+11,500
New +$89.3K 0.01% 517

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paradigm Asset Management's IBRX Position: Q3 2016 in Review

Paradigm Asset Management sold out of ImmunityBio (IBRX) in Q3 2016, closing a stake of 11,500 shares — an estimated $71.5K sold.

Paradigm Asset Management first reported a position in IBRX in Q2 2016 and held it in 1 quarter. The position peaked at $71.5K in Q2 2016. 63 funds tracked by Wall St. Rank hold IBRX as of Q3 2016.

  • Paradigm Asset Management reported no remaining ImmunityBio position as of Q3 2016 after selling out during the quarter.
  • Paradigm Asset Management sold 11,500 ImmunityBio shares in Q3 2016, an estimated $71.5K.
  • Paradigm Asset Management first reported a position in ImmunityBio in Q2 2016 and held it in 1 quarter.
  • Paradigm Asset Management's ImmunityBio position peaked at $71.5K in Q2 2016.
  • 63 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2016.

Based on Paradigm Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.